These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32810393)

  • 21. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
    Vilimas T
    Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Huang T; Liang Y; Zhang H; Chen X; Wei H; Sun W; Wang Y
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
    Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
    BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
    Luo C; Chen J; Chen L
    Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
    Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
    Front Immunol; 2021; 12():729359. PubMed ID: 34566988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
    Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive Value of
    Chen XJ; Ren AQ; Zheng L; Zheng ED
    Front Immunol; 2021; 12():664847. PubMed ID: 33953726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
    Coleman S; Xie M; Tarhini AA; Tan AC
    Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune cell infiltration-associated signature in colon cancer and its prognostic implications.
    Deng D; Luo X; Zhang S; Xu Z
    Aging (Albany NY); 2021 Aug; 13(15):19696-19709. PubMed ID: 34349038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
    Luo Y; Chen Q; Lin J
    Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types.
    Szabo PM; Pant S; Ely S; Desai K; Anguiano E; Wang L; Edwards R; Green G; Zhang N
    J Mol Diagn; 2021 Sep; 23(9):1159-1173. PubMed ID: 34197924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
    Lv J; Zhu Y; Ji A; Zhang Q; Liao G
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
    Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
    Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.
    Georgoulias G; Zaravinos A
    Front Immunol; 2022; 13():1006665. PubMed ID: 36389735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.